Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Inclusion Criteria: * English-speaking * Diagnosis of American Urological Association (AUA) high-risk non-muscle invasive bladder cancer (NMIBC), including high grade (HG) pT1 (invading only the lamina propria of the bladder), recurrent HG pTa (superficial tumors), HG pTa \> 3 cm in size or multifocal, any carcinoma in situ, any variant histology, any lymphovascular invasion, and HG prostatic urethral involvement * Diagnosis with urothelial carcinoma (primary histologic subtype), localized to the bladder, in the absence of nodal or other visceral metastases * Patients who have been indicated for induction intravesical BCG in shared-decision-making with their primary urologist * Have not received acupuncture in the previous 3 months * Access to phone for study contacts * Willing and able to participate in trial activities * Platelets: 20,000/ uL or greater * Absolute neutrophil count (ANC): 500 cells/uL or greater * Able to understand and willing to sign written informed consent in English Exclusion Criteria: * Subjects who have had intravesical or systemic chemotherapy or radiation therapy for bladder cancer or for other malignancies prior to entering the study * Subjects who are indicated to receive other intravesical agents or therapies concurrently with BCG will be excluded * Subjects who have muscle-invasive bladder cancer, radiographic evidence of lymph node metastases or metastatic disease involving other organs including brain metastases * Patients with predominant …